genuine question about 503B that I am slightly embarrassed to ask
genuine question about 503B that I am slightly embarrassed to ask — that is what I am asking, and I have already read the wiki twice.
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
Left up. It describes an arrangement with specifics and it is honest about the jurisdiction.
Was there potency testing on the finished preparation, or only on the starting material?
[deleted]
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
Right, and the concentration genuinely can differ from the branded product, which breaks people’s arithmetic.
This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.
a telehealth intake that asks nothing has told you what it is
the label on a compounded vial is a legal document, read it
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Compounded preparations are not approved products and carry no bioequivalence claim.
Agreed — and the follow-up question is what the beyond-use date is based on.
Agreed on potency testing of the finished preparation. That is a different question from the purity of the starting material.
ask what the beyond-use date is based on
do not assume the concentration matches the branded product
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
- 1Compounded preparations are not approved products and carry no…9 comments in this branch · started by u/lift_heavy_things